Surefire Medical to Change Name to TriSalus Life Sciences

New Company Name Better Represents Contribution to Patient Care

DENVER–(BUSINESS WIRE)–Surefire Medical, Inc. (Surefire) announced today the company is
changing its name to TriSalus Life Sciences to better reflect the
company’s contribution to patient care. TriSalus is focused on
developing drug delivery technology for use in solid tumors and
improving the administration of immuno-oncology (IO) therapies.

The re-naming of our company to TriSalus Life Sciences reflects an
important step in our journey to build a leading oncology drug delivery
company,” said TriSalus CEO Mary Szela. “As researchers identify more
ways to fight cancer, successful outcomes for patients are increasingly
being defined by three strategic pillars for oncology treatment: the
administration of the right therapeutic, the stimulation of the immune
system, and equally important: a targeted delivery system to augment the
therapeutic index.”

TriSalus derives from the Roman goddess Salus, who represents health,
prosperity, safety and welfare, while tri, represents the three
strategic pillars of integrated cancer treatment. “The new name inspires
our organization to make a meaningful difference for patients undergoing
cancer treatment,” added Szela.

The name change is one of many milestones supporting the transformation
of the company. In 2018, the company:

  • Advanced its pipeline of drug delivery therapies with plans to launch
    its next-generation platform in 2019
  • Presented interim data from a national patient registry showing high
    tumor response rates among hepatocellular carcinoma patients treated
    with the company’s Pressure-Enabled Drug Delivery (PEDD) technology
  • Published a paper in the Journal of Vascular and Interventional
    Radiology
    indicating that further development of chimeric antigen
    receptor T cells (CAR-T) therapy should be done in combination with
    novel devices to allow for regional delivery of therapy into solid
    tumors
  • Closed a $5 million convertible note and initiated plans for Series E
    funding of $25 million to support investment in the company’s
    technology in combination with immuno-oncology therapy

About Pressure-enabled Drug Delivery™ (PEDD)

The high intratumoral pressure created by the tumor microenvironment
limits the flow and accumulation of therapy in solid tumors.
Pressure-Enabled Drug DeliveryTM (PEDD) can improve drug
delivery to the tumor by creating a favorable pressure gradient that
penetrates the hostile tumor microenvironment and increases drug
concentration in the tumor without increasing systemic toxicity.
Locoregional infusion with the company’s patented technology has been
used in nearly 8,000 procedures worldwide for liver cancer and can be
applied to a variety of other high-pressure solid tumors.

About TriSalus Life Sciences

TriSalus Life Sciences, previously known as Surefire Medical, is a
privately held medical device firm in Westminster, CO, focused on making
the administration of cancer therapies safer and more effective for
patients. The company created the Pressure-Enabled Drug Delivery™ (PEDD)
technology and is committed to developing other applications of the
technology for use in other solid tumors and for the administration of
immuno-oncology (IO) therapies. TriSalus Life Sciences was founded in
2011.

MKT-0248 R01

Contacts

Outcomes Communication Group
Laureen Cassidy
laureen@outcomescg.com

Leave a Reply

Sky Optics Media drone video